House
Sign inCreate account
Drug lookup
Drug reference

brolucizumab

humanized single-chain antibody fragment, anti-VEGF · ophthalmological, anti-angiogenic

humanized single-chain antibody fragment, anti-VEGFophthalmological, anti-angiogenic
CDSCO approved
EXCRETION
—
not curated
INTERACTIONS
—
none in our sources
PREGNANCY
—
not curated

Mechanism

Brolucizumab is a humanized single-chain antibody fragment against VEGF.

Indications

wet macular degenerationmacular degeneration

Dosing

Adult
intravitreal injection

Side effects

Common
uveitis
Serious
  • severe inflammatory reaction

Related guidelines

Asthma in adults
GINA · Pulmonology · 2024
Acute coronary syndrome
ESC · Cardiology · 2023
Diabetic retinopathy
RSSDI · Ophthalmology · 2023
Diabetic retinopathy
AIOS · Ophthalmology · 2023
Induction of labour
FOGSI · Obstetrics & Gynaecology · 2019

Ask House about brolucizumab

Continue into a citation-backed clinical answer with the drug context already attached.

Open in workspaceAsk House about this drug

Sources: Goodman & Gilman 14e·Verified: 2026-05-10 · House clinical team